Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2020

View Archived Issues

The world according to GARP

SGT-001 data support potential for treating Duchenne muscular dystrophy

Shorter telomere length tied to moderate to severe COPD

ViiV Healthcare patents new antivirals for HIV-1 infection

Topline phase I data and interim phase I/II results presented for Trappsol Cyclo in NPC1

CODA Biotherapeutics enters research collaboration with the FPRF

FDA approves IND application for phase III study of Octagam 10% in severe COVID-19 patients

Janssen Pharmaceutica discloses SGLT2 inhibitors

FDA clears IND application for FT-538

AiCuris identifies HBV capsid assembly inhibitors

MyoKardia synthesizes new cardiac myosin inhibitors

Targovax presents next-generation ONCOS virus, ONCOS-214

Novel mouse model for small cell carcinoma of bladder

Amygdala contains pain suppression circuit

Merck & Co. describes new SCN10A channel blockers

Antiviral Fc-conjugate CD-377 shows potent activity against influenza

CanSino initiates phase I trial of PCV13i vaccine

Administration of scAAV9.CLN8 shows promise for treating CLN8-driven Batten disease

Anavex receives Australian clearance for first-in-human study of ANAVEX 3-71

FDA clears Alethia's IND for phase II study of AB-16B5 in NSCLC

Topline phase IIb/III data reported for filgotinib in moderate to severely active ulcerative colitis

PDE2 plus PDE9 inhibition synergistically improves synaptic plasticity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...